Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL3290266

CCNC(=O)OC(C)(C)C.N

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.52
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
GAA P10253 1/20 0.48
MAOA P21397 1/20 0.44
MAOB P27338 1/20 0.44
CA1 P00915 4/20 0.43
CA12 O43570 3/20 0.43
CA7 P43166 2/20 0.43
CA14 Q9ULX7 1/20 0.43
CTSK P43235 4/20 0.42
CA2 P00918 3/20 0.42
CTSS P25774 3/20 0.42
CA9 Q16790 2/20 0.42
EPHX1 P07099 2/20 0.42
CAPN1 P07384 1/20 0.41
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL967503 0.98 TDP1 (0.53) TDP1MEN1KMT2AGAAMAOA
SCHEMBL27996450 0.95 TDP1 (0.52) TDP1MEN1KMT2AGAAMAOA
Hydroxyamine SCHEMBL10630230 0.93 TDP1 (0.50) TDP1MEN1KMT2AGAAMAOA
SCHEMBL14717853 0.89 TDP1 (0.47) TDP1MEN1KMT2AGAAMAOA
SCHEMBL28706944 0.87 TDP1 (0.46) TDP1MEN1KMT2AGAAMAOA
SCHEMBL11168531 0.86 MAOA (0.46) TDP1MEN1KMT2AGAAMAOA
Dichloroacetic Acid SCHEMBL28652128 0.84 MEN1 (0.53) TDP1MEN1KMT2AGAAMAOA
SCHEMBL27822268 0.84 MEN1 (0.45) TDP1MEN1KMT2AGAAMAOA
SCHEMBL9476914 0.83 EPHX1 (0.41) TDP1MEN1KMT2AGAAMAOA
SCHEMBL3984277 0.83 TDP1 (0.46) TDP1MEN1KMT2AGAAMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8937152-B2 Non-selective somatostatin analogues ITALFARMACO SPA (IT) 2015-01-20 US disclosed
EP-2225271-B1 NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES ITALFARMACO SPA (IT) 2013-07-31 EP disclosed
US-20100323964-A1 NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES ITALFARMACO SPA (IT) 2010-12-23 US disclosed
EP-2225271-A2 NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES ITALFARMACO S.p.A. (IT) 2010-09-08 EP disclosed
US-7718157-B1 Targeted lipid particles BAKER TERENCE SEWARD 2010-05-18 US disclosed
WO-2009071460-A2 NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES ITALFARMACO SPA (IT) 2009-06-11 WO disclosed
EP-2067786-A1 Novel non selective analogs of somatostatin ITALFARMACO S.p.A. (IT) 2009-06-10 EP disclosed
US-7531676-B2 Lipids CELLTECH R & D LIMITED (GB) 2009-05-12 US disclosed
US-20060148761-A1 Lipids CELLTECH R & D LIMITED 2006-07-06 US disclosed
US-20040024220-A1 Lipids CELLTECH R & D LIMITED 2004-02-05 US disclosed
US-6583301-B1 Bipolar; form complexes with polyanions; delivering bioactive substances such as nucleic acids to cells in vitro and in vivo CELLTECH R & D LIMITED (GB) 2003-06-24 US disclosed
EP-1070047-A2 LIPIDS Celltech Chiroscience Limited (GB) 2001-01-24 EP disclosed
WO-1999052858-A2 LIPIDS CELLTECH THERAPEUTICS LIMITED (GB) 1999-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024220-A1 Lipids PHOSPHO1, FABP7, MBOAT7 TDP1 1253/4885MEN1 1304/4885KMT2A 3580/4885
US-20060148761-A1 Lipids PHOSPHO1, FABP7, MBOAT7 TDP1 1253/4885MEN1 1304/4885KMT2A 3580/4885
US-20100323964-A1 NEW NON-SELECTIVE SOMATOSTATIN ANALOGUES SSTR4, SSTR1, SSTR3 TDP1 4282/4885MEN1 115/4885KMT2A 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.